These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37699574)

  • 1. Myeloperoxidase creates a permissive microenvironmental niche for the progression of multiple myeloma.
    Williams CMD; Noll JE; Bradey AL; Duggan J; Wilczek VJ; Masavuli MG; Grubor-Bauk B; Panagopoulos RA; Hewett DR; Mrozik KM; Zannettino ACW; Vandyke K; Panagopoulos V
    Br J Haematol; 2023 Nov; 203(4):614-624. PubMed ID: 37699574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
    Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
    Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.
    Zhuang J; Zhang J; Lwin ST; Edwards JR; Edwards CM; Mundy GR; Yang X
    PLoS One; 2012; 7(11):e48871. PubMed ID: 23173040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
    Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
    Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma.
    Liu TW; Gammon ST; Yang P; Ma W; Wang J; Piwnica-Worms D
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36805920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone marrow myeloid cells in regulation of multiple myeloma progression.
    Herlihy SE; Lin C; Nefedova Y
    Cancer Immunol Immunother; 2017 Aug; 66(8):1007-1014. PubMed ID: 28378067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autocrine amplification of immature myeloid cells by IL-6 in multiple myeloma-infiltrated bone marrow.
    Matthes T; Manfroi B; Zeller A; Dunand-Sauthier I; Bogen B; Huard B
    Leukemia; 2015 Sep; 29(9):1882-90. PubMed ID: 26159051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression.
    Wang J; De Veirman K; Faict S; Frassanito MA; Ribatti D; Vacca A; Menu E
    J Pathol; 2016 Jun; 239(2):162-73. PubMed ID: 26956697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
    De Beule N; De Veirman K; Maes K; De Bruyne E; Menu E; Breckpot K; De Raeve H; Van Rampelbergh R; Van Ginderachter JA; Schots R; Van Valckenborgh E; Vanderkerken K
    J Pathol; 2017 Mar; 241(4):534-546. PubMed ID: 27976373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
    Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
    Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelopoiesis dysregulation associated to sustained APRIL production in multiple myeloma-infiltrated bone marrow.
    Matthes T; McKee T; Dunand-Sauthier I; Manfroi B; Park S; Passweg J; Huard B
    Leukemia; 2015 Sep; 29(9):1901-8. PubMed ID: 25753925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.
    Ramachandran IR; Martner A; Pisklakova A; Condamine T; Chase T; Vogl T; Roth J; Gabrilovich D; Nefedova Y
    J Immunol; 2013 Apr; 190(7):3815-23. PubMed ID: 23460744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.
    De Veirman K; Van Ginderachter JA; Lub S; De Beule N; Thielemans K; Bautmans I; Oyajobi BO; De Bruyne E; Menu E; Lemaire M; Van Riet I; Vanderkerken K; Van Valckenborgh E
    Oncotarget; 2015 Apr; 6(12):10532-47. PubMed ID: 25871384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
    Fan R; Satilmis H; Vandewalle N; Verheye E; Vlummens P; Maes A; Muylaert C; De Bruyne E; Menu E; Evans H; Chantry A; De Beule N; Hose D; Törngren M; Eriksson H; Vanderkerken K; Maes K; Breckpot K; De Veirman K
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36650020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.
    Ramachandran IR; Condamine T; Lin C; Herlihy SE; Garfall A; Vogl DT; Gabrilovich DI; Nefedova Y
    Cancer Lett; 2016 Feb; 371(1):117-24. PubMed ID: 26639197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma.
    Mrozik KM; Cheong CM; Hewett D; Chow AW; Blaschuk OW; Zannettino AC; Vandyke K
    Br J Haematol; 2015 Nov; 171(3):387-99. PubMed ID: 26194766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
    Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloperoxidase exerts anti-tumor activity in glioma after radiotherapy.
    Ali M; Fulci G; Grigalavicius M; Pulli B; Li A; Wojtkiewicz GR; Wang C; Hsieh KL; Linnoila JJ; Theodossiou TA; Chen JW
    Neoplasia; 2022 Apr; 26():100779. PubMed ID: 35247801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo.
    Cheong CM; Chow AW; Fitter S; Hewett DR; Martin SK; Williams SA; To LB; Zannettino AC; Vandyke K
    Exp Cell Res; 2015 Mar; 332(1):24-38. PubMed ID: 25637218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.
    Hewett DR; Vandyke K; Lawrence DM; Friend N; Noll JE; Geoghegan JM; Croucher PI; Zannettino ACW
    Neoplasia; 2017 Dec; 19(12):972-981. PubMed ID: 29091798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.